23andme Inc. of South San Francisco, and Pfizer Inc., of New York, have expanded an existing research agreement to provide Pfizer with access to 23andme's research platform, including services and analysis of the consumer genetics company's genotyped population of more than 800,000 customers, 80 percent of which have granted their consent to participate in research.